Privi Speciality Chemicals Reports Strong Q2 FY27 Results with 13.9% Revenue Growth
Privi Speciality Chemicals reported Q2 FY27 total income of ₹773.16 crore (up 13.9% YoY) and Net Profit of ₹117.03 crore (up 24.6% YoY). For H1 FY27, income grew 16.7% to ₹1,454.59 crore and profit rose 29.1% to ₹201.23 crore. Expansion projects are set for H2 2028. The company aims for ₹5,000 Cr revenue and ₹1,000 Cr EBITDA by FY29-30.
The announcement details significant financial performance improvements and provides a clear strategic roadmap with ambitious growth targets, which are material for investors.
The company reported strong year-on-year growth in revenue and net profit, along with improved margins and debt reduction metrics. The forward-looking statements and strategic plans indicate a positive outlook.
Privi Speciality Chemicals Limited announced its financial and operational results for the quarter and half-year ended September 30, 2026. The company reported a total income of ₹773.16 crore for Q2 FY27, marking a 13.90% year-on-year growth. EBITDA stood at ₹212.49 crore, an increase of 16.66% YoY, with an EBITDA margin of 27.5%. Net Profit for the quarter was ₹117.03 crore, up by 24.61% YoY. For the half-year ended September 30, 2026 (H1 FY27), total income grew by 16.7% YoY to ₹1,454.59 crore, and Net Profit increased by 29.1% YoY to ₹201.23 crore.
The company highlighted the resilience of its business model and disciplined execution despite global headwinds. Diversified geographic presence contributed to market stability. Expansion projects are progressing as planned and are expected to be ready for commercial operations in the second half of 2028. New products are anticipated to expand the addressable market and deepen customer relationships.
Key financial metrics for Q2 FY27 include Revenue of ₹773.16 crore (+13.9% YoY), EBITDA of ₹212.49 crore (+16.7% YoY) with a margin of 27.48% (+65 bps YoY), and PAT of ₹117.03 crore (+24.6% YoY). Return on Capital Employed (ROCE) stood at 26.34% (+134 bps YoY), and Return on Equity (ROE) was 24.30% (+216 bps YoY). Net Debt to EBITDA improved by 32.1% YoY to 1.07x, and Net Debt to Equity improved by 37.9% YoY to 0.51x.
The company is on track to achieve its vision of ₹5,000 crore revenue and ₹1,000 crore+ EBITDA by FY29-30, with EBITDA margins expected to sustain above 20%. The strategic merger of Privial, Anethole, and Cyclamen Aldehyde (PFSPL) and Privi Biotechnologies Private Limited (PBPL) into Privi Speciality Chemicals Limited (PSCL) is planned to strengthen core operations and enhance agility.
What to do with a filing like this
Privi Speciality Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Privi Speciality Chemicals Limited. Read the original for the full detail.